<DOC>
	<DOCNO>NCT01335399</DOCNO>
	<brief_summary>The purpose study determine whether addition Elotuzumab Lenalidomide/low-dose Dexamethasone increase progression free survival ( PFS )</brief_summary>
	<brief_title>Phase III Study Lenalidomide Dexamethasone With Without Elotuzumab Treat Newly Diagnosed , Previously Untreated Multiple Myeloma</brief_title>
	<detailed_description />
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com . Subjects newly diagnose symptomatic Multiple Myeloma ( MM ) : receive prior systemic antimyeloma therapy AND measurable disease AND candidate highdose therapy plus stemcell transplantation ( SCT ) age ( â‰¥ 65 year ) coexist condition . Refusal undergo high dose therapy SCT NOT sufficient entry onto CA204006 subject &lt; 65 year old . There must comorbidity prevents SCT subject &lt; 65 year old Subjects nonsecretory oligosecretory free lightchain myeloma Smoldering MM , define asymptomatic MM absence lytic bone lesion Monoclonal Gammopathy Undetermined Significance ( MGUS ) Active plasma cell leukemia Known Human Immunodeficiency Virus ( HIV ) infection active hepatitis A , B , C</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Newly Diagnosed</keyword>
	<keyword>Previously Untreated</keyword>
</DOC>